Could a new dosing schedule supercharge bone strength?
NCT ID NCT06059222
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study looks at whether giving the osteoporosis drug romosozumab in two separate 6-month blocks, with breaks for another drug called zoledronate, can build more bone than the standard 12-month course. It involves 270 postmenopausal women with osteoporosis and a recent fracture. The goal is to find the safest and most effective way to combine these medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Romosozumab (Evenity) and zoledronate
What this could lead to
If successful, this could identify a more effective dosing schedule for romosozumab and zoledronate, leading to stronger bones and fewer fractures in women with osteoporosis.
What could go wrong
This is a phase 4 trial with 270 participants, so results may not apply to all patients. Different dosing schedules may not improve outcomes and could carry risks like bone pain or rare jaw problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Osteoporosis Resistance Exercise Study (NCT05060380)
- Serum Lumican & Hidden Fragility in Postmenopaus NCT07677072
- Effervescent Calcium Magnesium Citrate Trial (NCT05998863)
- Functional Muscle-Bone Index Study (NCT07677033)
- Fragility Fracture Liaison Service Trial (NCT02194660)
- Osteoporosis Medication Monitoring Trial NCT02194647
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Endrocinology and Internal Medicine
RECRUITINGAarhus, 8000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••